1. 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. (September 2015) Authors: Lin, K.; Sun, J.; Maloney, L.; Goble, S.; Oza, A.; Coleman, R.; Scott, C.; Robillard, L.; Mann, E.; Isaacson, J.; Harding, T.; Giordano, H.; Rolfe, L.; McNeish, I.; Swisher, E.; Yelensky, R.; Allen, A.; Raponi, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors. (18th June 2013) Authors: Stuurman, F.E.; Lolkema, M.P.; Huitema, A.D.R.; Soetekouw, P.M.M.B.; Rosing, H.; Rolfe, L.; Kaur, P.; Beijnen, J.H.; van Tinteren, H.; Voest, E.E.; Schellens, J.H.M. Journal: Journal of clinical pharmacology Issue: Volume 53:Number 8(2013:Aug.) Page Start: 878 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). (February 2017) Authors: Oaknin, A.; Oza, A.; Tinker, A.V.; Ray-Coquard, I.; Coleman, R.; O'Malley, D.; Shapira-Frommer, R.; Leary, A.; Chen, L.M.; Provencher, D.; Ma, L.; Brenton, J.; Balmaña, J.; Giordano, H.; Maloney, L.; Goble, S.; Rolfe, L.; McNeish, I.; Swisher, E.; Kristeleit, R.S. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗